TSO3 to deliver presentation on prion sterilization research to experts at meeting hosted by France's Health Products Safety Agency (AFSSAPS)



    Stock symbol: TSX: TOS
    Outstanding shares: 47,863,402

    The Company will outline the latest data based on studies carried out by
    the Health Protection Agency of the United Kingdom and sponsored by the
    Department of Health on the effectiveness of its Ozone sterilization
    technology to eliminate prion infection

    QUEBEC, Jan. 12 /CNW Telbec/ - Mr. R.M. (Ric) Rumble, President and Chief
Executive Officer of TSO3 Inc. ("TSO3") (TSX: TOS), is pleased to announce
that the Company will be presenting data to France's experts on prion
inactivation methods for reusable medical devices. The Company will disclose
results of ongoing research pertaining to the use of its proprietary ozone
sterilization technology as a method for prion inactivation. This research
project, sponsored by the Department of Health of the United Kingdom and
contracted out to the Health Protection Agency, uses the TSO3 STERIZONE(R)
125L Ozone Sterilization Process to determine the effectiveness of the
technology in eliminating prion infection on medical instruments.
    The new data supports previous statements made in January 2008 that the
STERIZONE(R) 125L Ozone Sterilization Process shows promise as a technology
which could be used to reduce the risk of prion contamination. Additional
confirmation studies are still in progress and the Company expects results
from these studies in the coming months. The meeting, hosted by the French
Health Products Safety Agency (Afssaps), will be held January 13th in Paris,
France. Simon Robitaille, Chief Scientific Officer of TSO3, will be delivering
the presentation on behalf of the Company.
    "This meeting is part of a process aimed at helping France's Afssaps
establish a standard methodology for evaluating prion decontamination
technologies. Prions are abnormal proteins linked to Variant Creutzfeldt-Jakob
disease (vCJD). The goal of the meeting is to allow leading experts, such as
university-based scientists and hospital-based health professionals, to
exchange information on ways to compare the efficacy of different technologies
to one common standard," said Mr. Robitaille. "This invitation demonstrates
the level of recognition that our science is raising in the international
health safety field. I look forward to outlining our project to these experts
who have shown such an interest in our work," he added.

    About TSO3

    TSO3, founded in Québec City in 1998, specializes in the research and
development of innovative, high-performance medical instrument sterilization
technology with high commercial potential. The Company's first product, the
TSO3 STERIZONE(R) 125L Ozone Sterilizer, is designed for sterile processing
centers in the hospital environment.
    In contrast to other methods used, the ozone sterilization process
developed and patented by TSO3 meets all standards required by the evolution
in sterilization needs, which are: significant costs savings, increased safety
for patients and hospital staff, and a "green" environmentally safe process.
    The Company believes that its technology represents an advantageous
replacement solution to other low temperature sterilization processes
currently used in hospitals.
    TSO3 STERIZONE(R) 125L Ozone Sterilizer is cleared for commercialization
by the US Food and Drug Administration and by Health Canada. TSO3 is in
commercialization phase for this first product since 2006.
    For more information about TSO3, visit the Company's Web site at
www.tso3.com

    The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts
(including, without limitation, those regarding the timing or outcome of any
financing undertaken by TSO3 are forward-looking statements that involve
certain risks, uncertainties and hypotheses, including, but not limited to,
general business and economic conditions, the condition of the financial
markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.

    The TSX has neither approved nor disapproved the information contained
    herein and accepts no responsibility for it.




For further information:

For further information: Marc Boisjoli, Vice President Finance and Chief
Financial Officer, (418) 651-0003, ext. 228, mboisjoli@tso3.com; Frédéric
Tremblay, HKDP, (514) 395-0375, ext. 234, ir@tso3.com; Source: TSO3 Inc.


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890